Grant

A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 BiSpecific Antibody, Versus Investigator's Choice in Previously Untreated

Active

$7.5M Funding

3 People

External

Related Topics

immunotherapy, cancer treatment, biopharmaceuticals, clinical trials, monoclonal antibodies

People

Abhijeet Kumar
Principal Investigator (PI)
Medicine﹒Associate Professor, Medicine - (Clinical Scholar Track)
Michele Holland
(CD)
Cancer Center Division﹒Research Compliance Administrator II
Bital Savir-Baruch
Co-Investigator (COI)
Medical Imaging﹒Professor